Exploring barriers to resilience among preoperative non-small cell lung cancer patients: a qualitative study in China

探讨术前非小细胞肺癌患者心理韧性障碍:一项在中国开展的定性研究

阅读:1

Abstract

BACKGROUND: Resilience is crucial for lung cancer patients to navigate the challenges they face. However, current research on the barriers to resilience, particularly in relation to various levels of stressors, is limited. This study seeks to explore and analyze the barriers at various levels affecting resilience among preoperative lung cancer patients. METHODS: A descriptive phenomenological qualitative research method was employed, conducting semi-structured interviews with 23 patients who had received a preliminary diagnosis of lung cancer and were preparing for surgical treatment. Data were analyzed using Colaizzi's seven-step method within the social-ecological framework. RESULTS: Three categories and 11 themes were identified among lung cancer patients: (i) Micro-level system: Individual vulnerability (Fear of the unknown, Empathy for pain, Self-blame, Physical function decline, Waning interest). (ii) Meso-level system: Unstable family structure (Family enmeshment, Role conflicts, Communication barriers between couples). (iii) Macro-level system: Weak support systems (Lung cancer demonization, Workplace discrimination, Insufficient information support). CONCLUSION: This study sheds light on barriers to resilience at the individual, family, and societal levels among preoperative lung cancer patients. Given the variability in patient experiences, there is a critical need for patient-centered psychological, informational, and self-management support. Particularly in China, enhancing public awareness of lung cancer stands as a vital measure. Exploring the intricate dynamics of the empathy for pain, familial enmeshment, and the demonization of lung cancer emerges as pivotal areas for future inquiry. These knowledge can inform enhanced pain management strategies, improved family support systems, and a more accurate and less stigmatizing perception of lung cancer. TRIAL REGISTRATION: The registered No. from Chinese Clinical Trial Registry (CHICTR) was ChiCTR2300074853 and the registration date is August 17, 2023 (Archived by Webcite at https://www.chictr.org.cn/showproj.html?proj=205091 ).

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。